Sagimet Biosciences Inc. Series A Common Stock (NASDAQ:SGMT) — Market Cap & Net Worth
Market Cap & Net Worth: Sagimet Biosciences Inc. Series A Common Stock (SGMT)
Sagimet Biosciences Inc. Series A Common Stock (NASDAQ:SGMT) has a market capitalization of $408.71 Million ($408.71 Million) as of June 20, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13429 globally and #3202 in its home market, demonstrating a 2.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sagimet Biosciences Inc. Series A Common Stock's stock price $6.68 by its total outstanding shares 61184313 (61.18 Million). Review SGMT total debt and obligations to assess the company's total debt and financial obligations.
Sagimet Biosciences Inc. Series A Common Stock Market Cap History: 2023 to 2026
Sagimet Biosciences Inc. Series A Common Stock's market capitalization history from 2023 to 2026. Data shows change from $331.62 Million to $408.71 Million (-25.69% CAGR).
Index Memberships
Sagimet Biosciences Inc. Series A Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.02% | #358 of 976 |
|
NASDAQ Composite
IXIC
|
$41.03 Trillion | 0.00% | #1300 of 3165 |
Weight: Sagimet Biosciences Inc. Series A Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sagimet Biosciences Inc. Series A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sagimet Biosciences Inc. Series A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
165.81x
Sagimet Biosciences Inc. Series A Common Stock's market cap is 165.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $331.62 Million | $2.00 Million | -$27.88 Million | 165.81x | N/A |
Competitor Companies of SGMT by Market Capitalization
Companies near Sagimet Biosciences Inc. Series A Common Stock in the global market cap rankings as of June 20, 2026.
Key companies related to Sagimet Biosciences Inc. Series A Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Sagimet Biosciences Inc. Series A Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, Sagimet Biosciences Inc. Series A Common Stock's market cap moved from $331.62 Million to $ 408.71 Million, with a yearly change of -25.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $408.71 Million | +12.84% |
| 2025 | $362.21 Million | +26.50% |
| 2024 | $286.34 Million | -13.65% |
| 2023 | $331.62 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Sagimet Biosciences Inc. Series A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $408.71 Million USD |
| MoneyControl | $408.71 Million USD |
| MarketWatch | $408.71 Million USD |
| marketcap.company | $408.71 Million USD |
| Reuters | $408.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfun… Read more